<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655678</url>
  </required_header>
  <id_info>
    <org_study_id>CTX001-111</org_study_id>
    <nct_id>NCT03655678</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia</brief_title>
  <official_title>A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in subjects with&#xD;
      transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of&#xD;
      autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs)&#xD;
      using CTX001.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving transfusion independence for at least 12 consecutive months (TI12)</measure>
    <time_frame>From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days)</measure>
    <time_frame>Within 42 days after CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil and platelet engraftment</measure>
    <time_frame>Days post-infusion to engraftment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of collected adverse events (AEs)</measure>
    <time_frame>Signing of informed consent through Month 24 visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of transplant-related mortality (TRM)</measure>
    <time_frame>Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Signing of informed consent through Month 24 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving transfusion independence for at least 6 consecutive months (TI6)</measure>
    <time_frame>From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving at least 95 percent (%), 90%, 85%, 75%, and 50% reduction from baseline in annualized transfusions 60 days after CTX001 infusion</measure>
    <time_frame>From Day 60 up to 24 months post-CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in transfusions 60 days after CTX001 infusion</measure>
    <time_frame>From Day 60 up to 24 months post-CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of transfusion free in subjects who have achieved TI12</measure>
    <time_frame>From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of alleles with intended genetic modification in peripheral blood leukocytes over time</measure>
    <time_frame>Day 1 CTX001 infusion through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of alleles with intended genetic modification present in CD34+ cells of bone marrow over time</measure>
    <time_frame>Day 1 CTX001 infusion through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fetal hemoglobin concentration over time</measure>
    <time_frame>Baseline (pre-transfusion) through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total hemoglobin concentration over time</measure>
    <time_frame>Baseline (pre-transfusion) through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (HRQoL) from baseline over time using EuroQol Questionnaire (5 dimensions - 5 levels of severity - EQ-5D-5L)</measure>
    <time_frame>Screening visit through Month 24 visit</time_frame>
    <description>The EQ-5D-5L Questionnaire consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and 5 levels: no problems to extreme problems. The subject marks the most appropriate statement in each dimension, resulting in a 1-digit number for that dimension. The digits can be combined in a 5-digit number describing the subject's health state. The EQ VAS records the subject's self-rated health on a 100-point VAS, endpoints labelled &quot;the best health you can imagine&quot; and &quot;the worst health you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (HRQoL) from baseline over time using the Functional assessment of cancer therapy-bone marrow transplant questionnaire (FACT-BMT)</measure>
    <time_frame>Screening visit through Month 24 visit</time_frame>
    <description>The FACT-BMT Questionnaire includes physical, social, family, emotional, and functional well-being, and treatment specific concerns of bone marrow transplantation. Each statement has a 5-point Likert-type response scale ranging from 0=not at all to 4=very much. The subject marks one number per line as it applies to the past 7 days. Questionnaires are scored; the higher the score, the better the QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcome (PRO) over time assessed using EQ-5D-Youth (EQ-5D-Y)</measure>
    <time_frame>Screening visit through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PRO over time assessed using pediatric quality of life inventory (PedsQL)</measure>
    <time_frame>Screening visit through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver iron concentration (LIC) and cardiac iron content (CIC) and ferritin parameters of iron overload</measure>
    <time_frame>Screening visit through Month 24 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving iron chelation therapy</measure>
    <time_frame>1 month post-CTX001 infusion through Month 24 visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Beta-Thalassemia</condition>
  <condition>Thalassemia</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Hemoglobinopathies</condition>
  <arm_group>
    <arm_group_label>CTX001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX001</intervention_name>
    <description>Administered by IV infusion following myeloablative conditioning with busulfan</description>
    <arm_group_label>CTX001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by:&#xD;
&#xD;
               1. Documented homozygous β-thalassemia or compound heterozygous β-thalassemia&#xD;
                  including β-thalassemia/hemoglobin E (HbE). Subjects can be enrolled based on&#xD;
                  historical data, but a confirmation of the genotype using the study central&#xD;
                  laboratory will be required before busulfan conditioning.&#xD;
&#xD;
               2. History of at least 100 mL/kg/year or ≥10 units/year of packed RBC transfusions&#xD;
                  in the prior 2 years before signing the consent or the last rescreening for&#xD;
                  patients going through re-screening.&#xD;
&#xD;
          -  Eligible for autologous stem cell transplant as per investigator's judgment.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is&#xD;
             available per investigator's judgement.&#xD;
&#xD;
          -  Prior allo-HSCT.&#xD;
&#xD;
          -  Subjects with associated α-thalassemia and &gt;1 alpha deletion or alpha multiplications.&#xD;
&#xD;
          -  Subjects with sickle cell beta thalassemia variant.&#xD;
&#xD;
          -  Clinically significant and active bacterial, viral, fungal, or parasitic infection as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  White blood cell (WBC) count &lt;3 × 10^9/L or platelet count &lt;50 × 10^9/L not related to&#xD;
             hypersplenism.&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRISPR-Cas9</keyword>
  <keyword>Beta-Thalassemia</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

